STA
ALXN

Summit Trail Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Summit Trail Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-553
Closed -$69K – 1892
2017
Q4 		$69K Buy
+553
New +$67.3K 0.01% 733

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Summit Trail Advisors's ALXN Position: Q1 2018 in Review

Summit Trail Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q1 2018, closing a stake of 553 shares — an estimated $69K sold.

Summit Trail Advisors first reported a position in ALXN in Q4 2017 and held it in 1 quarter. The position peaked at $69K in Q4 2017. 596 funds tracked by Wall St. Rank hold ALXN as of Q1 2018.

  • Summit Trail Advisors reported no remaining Alexion Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Summit Trail Advisors sold 553 Alexion Pharmaceuticals shares in Q1 2018, an estimated $69K.
  • Summit Trail Advisors first reported a position in Alexion Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Summit Trail Advisors's Alexion Pharmaceuticals position peaked at $69K in Q4 2017.
  • 596 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2018.

Based on Summit Trail Advisors's 13F filing for Q1 2018, filed 21 May 2018.